1 2-grade improvement in the IGA score for the intertriginous area and the change in the Psoriasis Area

2 most clear plus a 2-grade improvement in the intertriginous-area IGA score occurred in 73% of the pat

3 ized by recurring suppurating lesions of the intertriginous areas, resulting in a substantial impact

4 e area, including scalp, face, trunk, and/or intertriginous areas.

5 compared to skin of healthy and perilesional intertriginous areas.

6 ecurrent vesicles and erosions mainly in the intertriginous areas.

7 , abscesses, and sinus tunnels, primarily in intertriginous areas.

8 for 8 in trial 1 and 9 in trial 2, including intertriginous IGA success (71.2% vs 13.8%; difference,

9   There were 9 secondary outcomes, including intertriginous IGA success, 75% reduction in Psoriasis A

10  stratified by site, baseline IGA score, and intertriginous involvement.

11 ely 15% of patients overall who had baseline intertriginous psoriasis of at least mild severity, an I

12  disease characterized by painful nodules in intertriginous regions that affects many pediatric patie

13 tracts, and scars occurring predominantly in intertriginous regions.

14 nic inflammatory disorder, which affects the intertriginous skin and is associated with numerous syst

15 se is a severe genetic blistering disease of intertriginous skin locations that can lead to poor qual